Kazia Therapeutics (KZIA) announced a research grant awarded from The Michael J. Fox Foundation for Parkinson’s Research, MJFF, to fund research between The Hebrew University of Jerusalem and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson’s disease. The grant will fund collaborative preclinical studies at Professor Ronit Sharons lab aimed at establishing an operational link between a specific pathway in the pathophysiology of PD and paxalisib. The research will assess the impact of paxalisib on mouse survival, motor and non-motor performances, as well as specific biochemical, pathological and molecular disease biomarkers that will be determined in brains of treated mice.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data
- Kazia Therapeutics initiated with a Buy at Maxim
- Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
- Kazia Therapeutics Launches Innovative Breast Cancer Trial with Paxalisib and Immunotherapy
- Kazia Therapeutics launches trial of paxalisib/immunotherapy combination